WallStreetZenWallStreetZen

NYSE: ABBV
Abbvie Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ABBV

Based on 14 analysts offering 12 month price targets for Abbvie Inc

Min Forecast
$220.00-2.38%
Avg Forecast
$253.50+12.48%
Max Forecast
$299.00+32.67%

Should I buy or sell ABBV stock?

Based on 14 analysts offering ratings for Abbvie Inc.

Strong Buy
Strong Buy
8 analysts 57.14%
Buy
3 analysts 21.43%
Hold
3 analysts 21.43%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their ABBV stock forecasts and price targets.

ABBV stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-02-25Find Out Why
lockedlocked$00.00+00.00%2026-02-20
lockedlocked$00.00+00.00%2026-02-18Find Out Why
lockedlocked$00.00+00.00%2026-02-05
lockedlocked$00.00+00.00%2026-02-05
Morgan Stanley
Top 6%
95
Strong BuyMaintains$270.00+19.80%2026-02-05
Citigroup
Top 13%
88
HoldMaintains$230.00+2.05%2026-01-27
HSBC
Top 32%
69
Strong BuyUpgrades$265.00+17.58%2025-12-10
UBS
Top 17%
84
HoldMaintains$220.00-2.38%2025-11-07Find out why
JP Morgan
Top 14%
87
Strong BuyMaintains$260.00+15.37%2025-11-03Find out why

1 of 2

Forecast return on equity

Is ABBV forecast to generate an efficient return?

Company
-1,061.96%
Industry
-51.16%
Market
180.91%
ABBV's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ABBV forecast to generate an efficient return on assets?

Company
25.92%
Industry
27.71%
ABBV is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ABBV earnings per share forecast

What is ABBV's earnings per share in the next 3 years based on estimates from 35 analysts?

Avg 1 year Forecast
$14.84+526.18%
Avg 2 year Forecast
$16.42+592.83%
Avg 3 year Forecast
$18.16+666.32%
ABBV's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

ABBV revenue forecast

What is ABBV's revenue in the next 3 years based on estimates from 34 analysts?

Avg 1 year Forecast
$68.4B+11.9%
Avg 2 year Forecast
$74.1B+21.12%
Avg 3 year Forecast
$79.6B+30.13%
ABBV's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ABBV earnings growth forecast

How is ABBV forecast to perform vs Drug Manufacturers - General companies and vs the US market?

Company
97.03%
Industry
30.89%
Market
36.28%
ABBV's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
ABBV's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
ABBV's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

ABBV revenue growth forecast

How is ABBV forecast to perform vs Drug Manufacturers - General companies and vs the US market?

Company
9.19%
Industry
9.26%
Market
13.49%
ABBV's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ABBV's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ABBV vs General Drug Manufacturer Stocks

TickerPricePrice TargetUp/downsideConsensus
ABBV$225.37$253.50+12.48%Strong Buy
AZN$192.50N/AN/A
NVS$154.25N/AN/A
MRK$115.91$124.29+7.23%Buy
JNJ$242.04$234.41-3.15%Buy
View Top General Drug Manufacturer Stocks

Abbvie Stock Forecast FAQ

Is Abbvie Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 14 Wall Street analysts covering (NYSE: ABBV) stock is to Strong Buy ABBV stock.

Out of 14 analysts, 8 (57.14%) are recommending ABBV as a Strong Buy, 3 (21.43%) are recommending ABBV as a Buy, 3 (21.43%) are recommending ABBV as a Hold, 0 (0%) are recommending ABBV as a Sell, and 0 (0%) are recommending ABBV as a Strong Sell.

If you're new to stock investing, here's how to buy Abbvie stock.

What is ABBV's earnings growth forecast for 2026-2028?

(NYSE: ABBV) Abbvie's forecast annual earnings growth rate of 97.03% is forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 30.89%, and it is also forecast to beat the US market's average forecast earnings growth rate of 36.28%.

Abbvie's earnings in 2026 is $4,226,000,000.On average, 35 Wall Street analysts forecast ABBV's earnings for 2026 to be $26,240,512,223, with the lowest ABBV earnings forecast at $24,519,199,689, and the highest ABBV earnings forecast at $28,312,806,305. On average, 33 Wall Street analysts forecast ABBV's earnings for 2027 to be $29,033,335,177, with the lowest ABBV earnings forecast at $25,905,444,195, and the highest ABBV earnings forecast at $32,360,145,173.

In 2028, ABBV is forecast to generate $32,113,131,962 in earnings, with the lowest earnings forecast at $26,979,783,687 and the highest earnings forecast at $36,184,694,746.

What is ABBV's revenue growth forecast for 2026-2028?

(NYSE: ABBV) Abbvie's forecast annual revenue growth rate of 9.19% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 9.26%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.49%.

Abbvie's revenue in 2026 is $61,160,000,000.On average, 34 Wall Street analysts forecast ABBV's revenue for 2026 to be $121,011,719,012,268, with the lowest ABBV revenue forecast at $115,408,391,413,240, and the highest ABBV revenue forecast at $125,400,314,500,052. On average, 33 Wall Street analysts forecast ABBV's revenue for 2027 to be $130,984,192,239,948, with the lowest ABBV revenue forecast at $122,557,098,728,756, and the highest ABBV revenue forecast at $137,874,746,879,712.

In 2028, ABBV is forecast to generate $140,723,267,158,044 in revenue, with the lowest revenue forecast at $128,781,053,650,996 and the highest revenue forecast at $150,075,113,062,512.

What is ABBV's forecast return on assets (ROA) for 2026-2029?

(NYSE: ABBV) forecast ROA is 25.92%, which is lower than the forecast US Drug Manufacturers - General industry average of 27.71%.

What is ABBV's Price Target?

According to 14 Wall Street analysts that have issued a 1 year ABBV price target, the average ABBV price target is $253.50, with the highest ABBV stock price forecast at $299.00 and the lowest ABBV stock price forecast at $220.00.

On average, Wall Street analysts predict that Abbvie's share price could reach $253.50 by Feb 25, 2027. The average Abbvie stock price prediction forecasts a potential upside of 12.48% from the current ABBV share price of $225.37.

What is ABBV's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSE: ABBV) Abbvie's current Earnings Per Share (EPS) is $2.37. On average, analysts forecast that ABBV's EPS will be $14.84 for 2026, with the lowest EPS forecast at $13.87, and the highest EPS forecast at $16.01. On average, analysts forecast that ABBV's EPS will be $16.42 for 2027, with the lowest EPS forecast at $14.65, and the highest EPS forecast at $18.30. In 2028, ABBV's EPS is forecast to hit $18.16 (min: $15.26, max: $20.46).

What is ABBV's forecast return on equity (ROE) for 2026-2029?

(NYSE: ABBV) forecast ROE is -1,061.96%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.